ALDEYRA THERAPEUTICS INC (ALDX)
US01438T1060 - Common Stock
Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
Tuesday's pre-market session: top gainers and losers
Get insights into the top gainers and losers of Tuesday's pre-market session.
Commit To Purchase Aldeyra Therapeutics At $2.50, Earn 25.2% Annualized Using Options
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases
Commit To Purchase Aldeyra Therapeutics At $2.50, Earn 22% Using Options
Aldeyra stock jumps 8% on dermatitis drug updates (NASDAQ:ALDX)
Aldeyra Therapeutics (ALDX) shares jumped 8% on updates for two of its drug candidates for atopic dermatitis. Read more here.
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis
3 Stocks at the Forefront of Personalized Medicine Trend
Unveiling the impact of personalized medicine stocks, transforming patient care, and propelling market growth seamlessly
FDA says more data needed to approve Aldeyra dry eye drug (NASDAQ:ALDX)
The FDA has declined to approve Aldeyra's (ALDX) drug reproxalap for dry eye disease, stating the company needs to run at least one additional study to show its effectiveness.
FDA says more studies needed to approve Aldeyra dry eye drug (NASDAQ:ALDX)
The FDA has declined to approve Aldeyra's (ALDX) drug reproxalap for dry eye disease, stating the company needs to run at least one additional study to show its effectiveness.
Why Are Stocks Up Today?
Stocks are up today as investors prepare for the most recent information from the Federal Reserve concerning interest rates.
Why Is Aldeyra Therapeutics (ALDX) Stock Up 40% Today?
Aldeyra Therapeutics stock is rising with heavy trading of ALDX shares after signing an exclusive option agreement with AbbVie.
Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap
NASDAQ:ALDX Long Term Investor Alert: Investigation over Potential Wrongdoing at Aldeyra Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 10/17/2023 -- Certain directors of Aldeyra Therapeutics, Inc. are under investigation over possible breaches of fiduciary duties.
Noteworthy Monday Option Activity: PRTA, IIPR, ALDX
Aldeyra says FDA may not approve dry eye drug, stock plunges 63% (ALDX)
Aldeyra shares plunged 63% after the company disclosed that the FDA may not approve its drug reproxalap for the treatment of dry eye disease due to insufficient efficacy data.
Commit To Purchase Aldeyra Therapeutics At $5, Earn 28.8% Annualized Using Options
DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 29 Deadline in Securities Class Action - ALDX
WHY: NEW YORK, NY - (NewMediaWire) - September 29, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between March 17, 2022 and June 20, 2023, both dates inclusive (the “Class Period”), of the important September 29, 2023 lead plaintiff deadline.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders of a Class Action against Aldeyra Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - ALDX
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:...